6505--Diclofenac Sodium (NA) 1% Gel
ID: 36E79725R0012Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/421859c493af4c1fb6c3d7cfef06934f/view
Timeline
  1. 1
    Posted Feb 10, 2025, 12:00 AM UTC
  2. 2
    Updated Feb 20, 2025, 12:00 AM UTC
  3. 3
    Due Mar 4, 2025, 8:30 PM UTC
Description

The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Diclofenac Sodium (NA) 1% Gel, intended for use in its pharmaceutical programs as well as those of the Department of Defense (DoD). Contractors are required to provide pricing for a base year along with four one-year option years, ensuring compliance with federal drug regulations and the Drug Supply Chain Security Act (DSCSA). This procurement is critical for maintaining a reliable supply of pharmaceutical products that meet stringent manufacturing standards and public health requirements. Interested parties must submit their offers by March 4, 2025, at 2:30 PM Central Time, and can contact Contract Specialist Ray Roldan at Raymond.Roldan@va.gov for further information.

Point(s) of Contact
Ray RoldanContract Specialist
Raymond.Roldan@va.gov
Files
Title
Posted
36E79725R0012.docx
Feb 20, 2025, 10:07 PM UTC
The document outlines a Request for Proposals (RFP) issued by the Department of Veterans Affairs (VA) for the supply of Diclofenac NA 1% Gel for the VA and Department of Defense (DoD) pharmaceutical programs. Key points include the requirement for potential contractors to provide pricing for a base year and four one-year option years, with specific instructions for submitting offers and samples. The contractor must adhere to established federal drug regulations and supply chain guidelines, including compliance with the Drug Supply Chain Security Act (DSCSA). The contract will be effective upon signing and will have set delivery and payment terms, with a unique focus on small businesses, including categories like women-owned and service-disabled veteran-owned businesses. The document emphasizes adherence to stringent manufacturing standards and the need for submitted products to have identifiable National Drug Codes (NDCs) or Universal Product Codes (UPCs). It highlights the government's commitment to maintaining compliance while ensuring consistent product availability through its prime vendor network. This RFP illustrates the structured process by which government contracts for pharmaceutical products are awarded, underscoring the criticality of compliance with regulatory standards designed to protect public health and ensure quality supply chains.
36E79725R0012 0001.docx
Feb 20, 2025, 10:07 PM UTC
The document is an amendment related to solicitation 36E79725R0012 for the procurement of Diclofenac Gel, issued by the Department of Veterans Affairs National Acquisition Center. The primary purpose of this amendment is to extend the deadline for submission of offers from February 25, 2025, to March 4, 2025, at 2:30 PM Central Time. The amendment stipulates that all other terms and conditions of the solicitation remain unchanged. The document specifies methods by which offerors can acknowledge receipt of the amendment, including providing signed copies or references in their submissions. The contracting officer responsible for this amendment is Nicholas I. McGregor, indicating formal oversight of the solicitation process. This document exemplifies typical practices and procedures in federal government contracting, highlighting the importance of deadlines and compliance with solicitation amendments in securing government contracts.
Lifecycle
Title
Type
6505--Diclofenac Sodium (NA) 1% Gel
Currently viewing
Solicitation
6505--Diclofenac Sodium (NA) 1% Gel
Presolicitation
Similar Opportunities
6505--Fludrocortisone Acetate Tablets (VA-25-00047932)
Buyer not available
The Department of Veterans Affairs is soliciting bids for the procurement of Fludrocortisone Acetate Tablets (0.1 MG) under the VA & DoD Pharmaceutical Prime Vendor Programs. Contractors are required to submit proposals that include pricing for a base year and four option years, adhering to specific guidelines such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act. This procurement is crucial for ensuring a consistent supply of essential pharmaceuticals to veterans, emphasizing the importance of Good Manufacturing Practices (cGMP) and the need for a unique National Drug Code (NDC) for each product offered. Interested contractors should contact Youlanda Duggar at youlanda.duggar@va.gov for further details and to ensure compliance with all submission requirements.
6505--Aprepitant Capsules
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the supply of Aprepitant capsules, a pharmaceutical product essential for various government health facilities, including those under the Department of Defense and Indian Health Service. Offerors are required to provide pricing for multiple line items covering a base year and four option years, adhering to specific conditions such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act (DSCSA). The contract emphasizes the importance of maintaining current Good Manufacturing Practices (cGMP) and ensuring proper labeling and packaging of the products. Interested contractors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details and must submit their proposals in accordance with the outlined requirements.
Dimethyl Fumarate DR Presolicitation
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
6505--Topiramate Tablets (VA-25-00047941)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Topiramate Tablets, designated as Solicitation 36E79725R0031. This procurement aims to secure an uninterrupted supply of various forms of Topiramate for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), highlighting the importance of ensuring continuous access to essential pharmaceuticals across federal health services. The contract will span one year with four additional pre-priced option years, and interested vendors must submit their proposals electronically by April 29, 2025, while providing the exact name of the drug along with a unique National Drug Code (NDC). For further inquiries, vendors can contact Contract Specialist Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
6505--Hydroxychloroquine SO4 Tablets
Buyer not available
The Department of Veterans Affairs is soliciting offers for the procurement of Hydroxychloroquine SO4 Tablets, specifically 200mg tablets, through its National Acquisition Center. The solicitation outlines the requirements for supply contracts, including compliance with Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), as well as the need for a unique National Drug Code (NDC) for each product. This procurement is crucial for ensuring a consistent supply of pharmaceuticals to government healthcare facilities, thereby maintaining availability and pricing stability. Interested contractors should note that the deadline for submitting offers has been extended to April 8, 2025, at 2:30 PM CDT, and can reach out to Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further inquiries.
Valsartan
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
6505--Acyclovir Capsules (VA-25-00048078)
Buyer not available
The Department of Veterans Affairs is seeking proposals for the procurement of Acyclovir Capsules, specifically 200MG capsules in two packaging sizes, to support the healthcare needs of veterans. The solicitation includes two line items: Line Item 1 requires 3,256 bottles of 100 capsules per bottle, and Line Item 2 requests 15,475 bottles of 500 capsules per bottle, with the same quantities needed for the base year and each of the four option years. This procurement is crucial for ensuring a reliable supply of essential pharmaceuticals for veterans, emphasizing the importance of compliance and competition within the pharmaceutical supply chain. Interested suppliers must submit their pricing proposals by May 1, 2025, and can contact Contracting Officer Andrew Cazares at andrew.cazaeres@va.gov or (708) 786-4990 for further details.
Solifenacin
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Solifenacin, specifically 5MG and 10MG tablets in 30 and 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Indian Health Service, and Bureau of Prisons through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should direct inquiries to Jayne Do at jayne.do@dla.mil, with the solicitation anticipated to be posted in April 2025 on the DLA Bid Board System and SAM.gov.
Duloxetine HCL DR Capsules
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR Capsules, which includes various dosages and packaging options. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in April 2025. Interested parties should direct inquiries to Christopher Newman at christopher.newman@dla.mil or 445-737-7371, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
6505--Perphenazine Tablets (VA-25-00037353)
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Perphenazine tablets under solicitation number VA-25-00037353. This contract aims to supply specified quantities of the drug to both the VA and the Department of Defense (DoD) through their Pharmaceutical Prime Vendor (PPV) Programs, with a focus on service-disabled veteran-owned small businesses, women-owned small businesses, and HUBZone small businesses. The procurement is critical for ensuring a consistent supply of pharmaceutical products while adhering to regulatory requirements, including the Drug Supply Chain Security Act (DSCSA) and FDA Good Manufacturing Practices (cGMP). Interested offerors must contact Contract Specialist Anthony DiCrescenzo at Anthony.DiCrescenzo@va.gov for further details, and proposals must include a 0.5% Cost Recovery Fee and a unique National Drug Code (NDC) for each product.